BioMedTracker's JPM Drug News: Day 3
This article was originally published in Scrip
Every day of the 34th annual JP Morgan Healthcare Conference in San Francisco, analysts from BioMedTracker – an affiliate of Scrip Intelligence – produce a report detailing the drug events and catalysts that are announced or updated at the meeting. See below for the highlights, and click on the link at the bottom for a complimentary copy of the full report.
You may also be interested in...
Mooted some time ago, the Medicare Part D Drug Rebate Rule and the Medicare Part B Most-Favored-Nation Model have now been finalized by US President Donald Trump. But US off-patent body the Association for Accessible Medicines feels “further action is necessary.”
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.